From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Confidence level
Lower limit of CI
Upper limit of CI
Sample size per arm
Total sample size
95%
80
96%
62
124
90%
50
100
80%
38
76